Q1
KMTS — Q1 2026 (Quarter Ended July 31, 2026) Financial Report Analysis
Kestra Medical grew revenue 60% to $31.0M and lifted gross margin 10.8 points to 56.5% on a 9% drop in cost per patient, but a commercial-hiring build-out and a $6.3M debt-refinancing charge widened net loss 71% to $44.1M, leaving roughly 18 months of runway on $244.7M of cash and investments.